Synovial Fibroblast 3.2: Secretion response of seven primary human synovial fibroblast samples from healthy and rheumatoid arthritis-diagnosed donors to a panel of 3 stimuli and 5 small molecule inhibitors (replicate 2 of 2) - Dataset (ID:20235)
- Detail
- Small Molecules Studied
- Primary Cells Studied
- Proteins Studied
- Unclassified Perturbagens Studied
- Data Columns
- Results
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | Protein Stimulus | Other Stimulus | Stimulus Concentration | Stimulus Conc Unit | ExpPlate | Measured Protein | Measured Protein MFI (a.u.) | Bead Count |
---|---|---|---|---|---|---|---|---|---|---|---|
RA2159 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 2 | VEGF | 661.5 | 72 | |
N2645 | 5z-7-oxozeaenol | 0.6 | uM | IL-1 alpha | 100 | ng/mL | 2 | VEGF | 581.5 | 64 | |
N2645 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 2 | VEGF | 913.0 | 62 | |
RA2708 | 5z-7-oxozeaenol | 0.6 | uM | IL-1 alpha | 100 | ng/mL | 2 | VEGF | 688.0 | 71 | |
RA2708 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 2 | VEGF | 586.0 | 71 | |
RA2159 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 2 | VEGF | 1122.0 | 40 | |
RA2159 | IL-1 alpha | 100 | ng/mL | 2 | VEGF | 931.5 | 84 | ||||
N2645 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 2 | VEGF | 1205.0 | 61 | |
N2645 | IL-1 alpha | 100 | ng/mL | 2 | VEGF | 1569.0 | 65 | ||||
RA2708 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 2 | VEGF | 1436.0 | 51 | |
RA2708 | IL-1 alpha | 100 | ng/mL | 2 | VEGF | 1480.5 | 60 | ||||
RA2159 | 5z-7-oxozeaenol | 0.6 | uM | Poly(I:C) | 2 | ug/mL | 2 | VEGF | 485.0 | 63 | |
RA2159 | IKK16 | 2.0 | uM | Poly(I:C) | 2 | ug/mL | 2 | VEGF | 623.0 | 69 | |
N2645 | 5z-7-oxozeaenol | 0.6 | uM | Poly(I:C) | 2 | ug/mL | 2 | VEGF | 462.0 | 67 | |
N2645 | IKK16 | 2.0 | uM | Poly(I:C) | 2 | ug/mL | 2 | VEGF | 603.0 | 70 | |
RA2708 | 5z-7-oxozeaenol | 0.6 | uM | Poly(I:C) | 2 | ug/mL | 2 | VEGF | 693.0 | 62 | |
RA2708 | IKK16 | 2.0 | uM | Poly(I:C) | 2 | ug/mL | 2 | VEGF | 581.5 | 58 | |
RA2159 | Tofacitinib | 0.3 | uM | Poly(I:C) | 2 | ug/mL | 2 | VEGF | 805.0 | 69 | |
RA2159 | Poly(I:C) | 2 | ug/mL | 2 | VEGF | 984.0 | 56 | ||||
N2645 | Tofacitinib | 0.3 | uM | Poly(I:C) | 2 | ug/mL | 2 | VEGF | 910.0 | 58 | |
N2645 | Poly(I:C) | 2 | ug/mL | 2 | VEGF | 925.0 | 59 | ||||
RA2708 | Tofacitinib | 0.3 | uM | Poly(I:C) | 2 | ug/mL | 2 | VEGF | 1286.0 | 71 | |
RA2708 | Poly(I:C) | 2 | ug/mL | 2 | VEGF | 1044.0 | 73 | ||||
RA2159 | 5z-7-oxozeaenol | 0.6 | uM | 2 | VEGF | 525.0 | 61 | ||||
RA2159 | IKK16 | 2.0 | uM | 2 | VEGF | 598.0 | 67 |